Comparative Pharmacology
Head-to-head clinical analysis: ISUPREL versus NORISODRINE AEROTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISUPREL versus NORISODRINE AEROTROL.
ISUPREL vs NORISODRINE AEROTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective beta-adrenergic agonist with predominant beta-1 and beta-2 receptor stimulation, leading to increased heart rate, contractility, and bronchodilation.
Isoproterenol is a non-selective beta-adrenergic receptor agonist, primarily stimulating both β1 and β2 receptors, resulting in increased heart rate, myocardial contractility, and bronchodilation.
Adult: 0.5-5 mcg/min IV infusion titrated to effect; bolus: 10-20 mcg IV push. Sublingual: 10-20 mg 3-4 times daily.
1 to 2 inhalations (0.08 to 0.16 mg) every 4 to 6 hours as needed for bronchospasm.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5-3 hours in adults. In neonates and infants, half-life may be longer (up to 6-8 hours). Clinical context: Short half-life necessitates continuous infusion for sustained effect in acute settings.
The terminal elimination half-life of isoproterenol is approximately 2-3 minutes following intravenous administration, due to rapid uptake into tissues and metabolism by catechol-O-methyltransferase (COMT). This short half-life necessitates continuous infusion for sustained effect.
Primarily renal excretion of unchanged drug and conjugates; approximately 50-70% excreted in urine within 24 hours (mostly as sulfate conjugates, with about 10-15% unchanged), and less than 5% in feces.
Primarily renal excretion of unchanged drug and metabolites (sulfate conjugates). After intravenous administration, approximately 70-80% of the dose is excreted in urine within 24 hours, with less than 10% in feces.
Category C
Category C
Beta-Adrenergic Agonist
Beta-Adrenergic Agonist